Oncology Xagena
Data from the coBRIM phase III study were presented at ESMO ( European Society of Medical Oncology ) 2014 Congress. The results have shown that people with previously untreated BRAF V600 mutation-po ...
The FDA ( Food and Drug Administration ) has granted Priority Review for the New Drug Application ( NDA ) for Cobimetinib in combination with Vemurafenib ( Zelboraf ) for the treatment of people with ...
Treatment of patients with BRAF V600–mutant melanoma includes BRAF/MEK-inhibitor combinations based on demonstrated benefits on progression-free survival ( PFS ) and overall survival ( OS ). To bett ...
